webleads-tracker

Home  >  MEDTECH  > How are NGS technologies revolutionizing the way we think ...
  >  MEDTECH
Aug 26th, 2013
 
How are NGS technologies revolutionizing the way we think about healthcare?
 
Yole Développement, announce its new technology & market analysis: Next Generation Sequencing (NGS).
Send to a friend

With this report, Yole Développement proposes you to learn more about the next generation sequencing market. “The Next Generation Sequencing (NGS) market will sharply grow from $2.2B to $4.4B in 2018”, announces Benjamin Roussel, Technology & Market Analyst, Microfluidics & Medical Technologies at Yole Développement. According to him, “This impressive 27% growth will be fueled mainly by huge investments recently made by diagnostic companies associated with the market entry of new products”.

Next Generation Sequencing technologies drive the way toward personalized medicine

Next Generation Sequencing (NGS) technologies have demonstrated the capacity to sequence DNA at unprecedented speed, enabling previously unimaginable novel healthcare applications. By providing valuable data on patient genomes, NGS technologies are filling the gap separating traditional and personalized medicine. Along with a global shift toward personalized medicine and through the development of advanced bioinformatic tools, NGS technologies will have a striking impact on cancer management, treatments of rare diseases and future developments of genetic therapies. The change will be gradual, starting with oncology where personalized medicine is more likely to be accepted. Physicians will have to change their way of working to take full advantage of this giant leap forward in medicine. To do so, medical school coursework will likely evolve in the near future to integrate how to work with genomics data.

The Next Generation Sequencing market is poised to reach $4.4B in 2018!

Starting its transition from research to clinical market, the Next Generation Sequencing (NGS) market will sharply grow from $2.2B to $4.4B in 2018. That impressive growth will be fueled by huge investments recently made by diagnostic companies (Thermo Fisher Scientific, Qiagen, Illumina…) associated with the market entry of new products (PII and PIII, Qiagen’s benchtop, Oxford Nanopore Technologies’ products…). Previously, the high cost of both sequencing machines and consumables limited the wide adoption of this technology. Today, those drawbacks have been resolved with the development of Next Generation Sequencing Technologies.The attractiveness of the NGS business has caused the number of suppliers to sharply increase over the last five years. Among them, Illumina is positioned in first place with around 46% of market share. Thermo Fisher Scientific, in second place, is the most important challenger. Our analysis provides 2013-2018 market data, along with player market shares at both the equipment and consumable levels. Moreover, positioning strategy of each supplier has been analyzed in the document.

 

 

 

Discover the NGS market’s complex organization, splitted in four segments

The market segmentation is a tool used to provide a vision of the market. Based on technical and economic criteria, fours segments have been identified: research, forensics, diagnostics and consumer. Until recently, uses of Next Generation Sequencing tools were limited to research (human whole genome, exome, small genome, targeted, transcriptome, RNA profiling, chIP-Seq, metagenomics…). Nowadays, NGS technologies have found applications mainly in two fields: clinical diagnostics and forensics.
Our investigation describes both current and future applications.

Next Generation Sequencing technologies overview

In April 2003, human genome project was declared complete. This first human genome sequencing took 13 years, mobilized 20000 researchers and cost $3B! Since the early 2000s, sequencing technologies have come a long way from Sanger sequencing (also called 1st generation sequencing) used for the human genome project to the Next Generation Sequencing technologies available today. By sequencing a large number of DNA molecules in parallel after PCR amplification, technology developers have been able to sharply increase machine throughput by a factor of 10, along with a steep price reduction.
The launch of a new detection method based on electrochemical detections was also a huge step forward for the sequencing world.
Today, based on these new technologies, we can sequence the whole human genome in less than three hours with one laboratory technician and a total cost around $1000. Technologies under development are poised to extend the boundaries with a targeted sequencing cost of $100. All technologies currently in use and those under development are presented in our report. Benchmarking is also presented for eight different sequencing applications.

New opportunities arise for cartridge makers

The wide adoption of NGS technology has changed the way NGS suppliers are generating revenue. A shift occurred in the sales mix, moving from instruments to consumables which have a higher gross margin than instruments. This leads to an increase in revenue based on consumable sales. The number of NGS Platforms used worldwide will exploded in the next several years and the run time will continue to decrease. Therefore, the market of NGS consumables will explode.
Yole Développement foresees the NGS Consumables Market growing to $3.1B in 2018, the result of several millions of cartridges being sold each year. For now, glass and silicon are the preferred materials used.

For more information about this report, please click here

 

 

 

 
More MEDTECH news

Aug 23rd
Aug 21st
Aug 21st
Aug 21st
Aug 13th
 
©2007 Yole Developpement All rights reserved                  Disclaimer | Legal notice | To advertise
Yole Développement: Le Quartz, 75 cours Emile Zola, 69100 Villeurbanne, France. TEL: (33) 472 83 01 80 FAX: (33) 472 83 01 83 E-Mail: info @yole.fr